Abstract

3-D Bioprinting and Organ on Chips for Drug Discovery and Development

Danilo Tagle, Associate Director for Special Initiatives, National Institutes of Health

About 90 percent of potential new drugs fail in clinical trials because they are found to be ineffective or due to adverse events. This failure happens in large part because 2D in vitro assays, and animal models used during the drug discovery and development process do not accurately predict human physiological response. To address this critical for better predictive tools, NCATS is supporting programs for 3-D bioprinting of human cells in microplate format for drug screening and discovery, and organs on chips that can be used for safety and efficacy assessments of the candidate drugs.